Skip to main content
. Author manuscript; available in PMC: 2021 May 10.
Published in final edited form as: J Control Release. 2020 Feb 3;321:1–22. doi: 10.1016/j.jconrel.2020.01.057

Fig. 6. Increased corneal retention and sustained release of drugs by combining in situ gels and NPs.

Fig. 6.

(A) Dynamic gamma scintigraphy study showing percentage radioactivity remaining on cornea with time (blue-diamond shape) marketed, (green triangle shape) chitosan in situ gel, (red-square shape) nanosuspension, (purple-circle shape) nanoparticle laden in situ gel (From [134]). (B) Concentration of ketarolac in aqueous humor of rabbit eyes with time from the nanodispersion (E2) and in situ gel incorporated with E2 (NG2) compared to Acular® eye drops (From [137]). (C) The difference of IOP between two eyes (i.e. IOP lowering effect) for (a) linear PNIPAAm eye drops; and (b) linear PNIPAAm and nanoparticles mixture eye drops (From [23]).